Characteristics of Severe Asthma Clinic Patients with Eosinophilic Granulomatosis with Polyangiitis

Youxin PUAN,Kheng Yong ONG,Pei Yee TIEW,Gabriel Xu Wen CHEN,Neville Wei Yang TEO,Andrea Hsiu Ling LOW,Michael E. WECHSLER,Mariko Siyue KOH
DOI: https://doi.org/10.1016/j.jaip.2024.10.013
IF: 11.022
2024-10-19
The Journal of Allergy and Clinical Immunology In Practice
Abstract:Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis associated with varying clinical presentations and overlapping multiorgan involvement. Asthma is a predominant feature of EGPA, typically in its prodromal phase, often severe and precedes vasculitic complications. However, there is paucity of studies describing the prevalence and characteristics of EGPA in the asthma population. Objective We aim to describe the clinical and serological characteristics and longitudinal therapeutic outcomes of patients with EGPA in the severe asthma (SA) cohort. Methods Retrospective study of patients with EGPA attending the multidisciplinary SA clinic in a tertiary hospital from 2011 to 2023 was conducted. Baseline demographics, organ manifestations, biological markers, lung function and therapeutic outcomes were assessed. Results 23 out of 596 patients in the SA registry were identified to have EGPA. Median time interval between asthma and EGPA diagnosis was 10 years (range 2.5 to 32 years). Almost all patients (95.7%) had peak blood eosinophil count of >1.0 x 10 9 /L (range 0.47 – 14.08 x 10 9 /L). Upper airway involvement was the most detected manifestation in addition to asthma, followed by neuropathy and renal involvement. Patients who were treated with biologic therapy were significantly younger, had more upper airway, renal, pulmonary involvement and lower five factor score (FFS). Conclusion The prevalence of EGPA in the SA population was 3.9% in our cohort. Its diagnosis requires high clinical suspicion in patients with SA and blood eosinophilia, prompting stringent evaluation for extrapulmonary manifestations and multidisciplinary involvement.
immunology,allergy
What problem does this paper attempt to address?